Loading patent…
AssigneeGeorgetown University
InventorsUsha Kasid, Prafulla Gokhale, Chuanbo Zhang, Anatoly Dritschilo, Aquilur Rahman
Estimating the term…
It is possible to radiosensitize tumor cells by administration of compositions containing the Human antisense c-raf-1 oligodeoxyribonucleotide (ODN/oligo) sequence: 5′-GTGCTCCATTGATGC-3′ (SEQ. ID. NO: 1) wherein only the end bases are phosphorothioated is a preferred embodiment. Antisense sequences of up to 40 bases which contain this sequence, such as 5′-CCTGTATGTGCTCCATTGATGCAGC-3′ (SEQ ID NO: 2) may be used in accord with the teachings of this disclosure. Compositions comprising a cationic liposome of dimethyldioctadecyl ammonium bromide, phosphatidylcholine and cholesterol may be used as a carrier system. The liposomes provide a new carrier system that is particularly useful for administration of sequences for therapy.
A composition comprising a cationic liposome comprising a cationic liposome containing a cationic lipid, phosphatidylcholine, cholesterol and an antisense oligonucleotide comprising a raf antisense oligonucleotide wherein the antisense oligonucleotide comprises a sequence of the formula 5′-CCTGTATGTGCTCCATTGATGCAGC-3′ (SEQ ID NO:
(canceled)
(canceled)
(canceled)
(canceled)
A method of radiosensitizing tumor tissue by administration of a radiosensitizing effective amount of least one antisense oligonucleotide of no more than 40 bases comprising the sequence 5′-CCTGTATGTGCTCCATTGATGCAGC-3′ (SEQ ID NO:
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.